-+ 0.00%
-+ 0.00%
-+ 0.00%

Zai Lab says China NMPA approves TIVDAK for recurrent or metastatic cervical cancer

PUBT·06/09/2026 00:34:20
Listen to the news
Zai Lab says China NMPA approves TIVDAK for recurrent or metastatic cervical cancer
  • Zai Lab secured China NMPA clearance for TIVDAK (tisotumab vedotin) in adults with recurrent or metastatic cervical cancer post-chemotherapy progression.
  • Approval relied on Phase 3 innovaTV 301 data showing an overall survival edge versus chemotherapy; global ITT hazard ratio 0.70.
  • China subgroup results aligned, with an OS hazard ratio of 0.55 versus chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606082034BIZWIRE_USPR_____20260608_BW963481) on June 09, 2026, and is solely responsible for the information contained therein.